https://www.clinicaltrialsarena.com/news/bellerophon-therapeutics-fild-trial/ Another company fails to make a difference to Pulmonay Fibrosis management. Using ambulatory inhaled Nirtic Oxide (currently NOxide used successfully in ICU for temporary severe Pulmonary Hypertension management). Logically this would only address symptoms and possibly slow secondary right heart failure rather than address the causative fibrosis. ATX has a massive potential here.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.010(6.45%) |
Mkt cap ! $84.65M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 16.5¢ | 14.8¢ | $148.7K | 950.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 514529 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 531002 | 2 |
View Market Depth
| Last trade - 16.10pm 12/09/2025 (20 minute delay) ? |
| ATX (ASX) Chart |